Pfizer and BioNTech have entered a letter of intent with South Africa-based The Biovac Institute for the manufacture of their Covid-19 vaccine to be supplied in the African Union. Biovac will handle production and supply activities within Pfizer and BioNTech’s global Covid-19 vaccine supply chain and manufacturing network. By the end of the year, Biovac’s Cape Town plant will be part of the vaccine supply chain and the yearly production is expected to reach more than 100 million finished doses at its full operational capacity.

Vietnamese pharmaceutical firm VABIOTECH has manufactured a test batch of the Russian Sputnik V Covid-19 vaccine. The Russian Direct Investment Fund noted that the Gamaleya Center will receive initial validation samples from the test batch for quality control purposes. Meanwhile, the Republic of Chile has approved Sputnik V, which currently holds approvals in 69 countries.

Sorrento Therapeutics has dosed participants in Phase II clinical trial of its intranasal therapy, COVIDROPS, in an at-home setting in the UK. The decentralised trial will enrol nearly 350 Covid-19 outpatients without symptoms or with mild symptoms. This study will support Phase II trials that are being commenced in the US. If positive data is obtained, the company intends to seek emergency use authorisation for the treatment in multiple countries, including the US, UK, India and Canada.